C4 Therapeutics Reports Q1 Results, Confirms Cash Runway to 2028, Details Roche Collaboration
CCCC has more than doubled off its 52-week low of $1.21.
Summary
C4 Therapeutics reported Q1 2026 results, confirming a cash runway through the end of 2028 and detailing a new, significant collaboration with Roche that includes a $20 million upfront payment and over $1 billion in potential milestones.
Key Events · Earnings and Guidance · CCCC
-
Q1 2026 Financial Results
The company reported a net loss of $25.1 million for Q1 2026, an improvement from $26.3 million in Q1 2025. Revenue from collaboration agreements decreased to $6.15 million from $7.24 million year-over-year, primarily due to a decrease in the MKDG collaboration and termination of the Merck collaboration, partially offset by a Biogen milestone.
-
Extended Cash Runway Confirmed
C4 Therapeutics confirmed its cash, cash equivalents, and marketable securities of $268.3 million as of March 31, 2026, are sufficient to fund operations through the end of 2028. This extends the company's financial stability significantly.
-
New Roche Collaboration Detailed
The company entered into a new Research Collaboration and License Agreement with Roche on April 8, 2026, for degrader-antibody conjugates (DACs). This agreement includes a $20 million upfront cash payment and eligibility for over $1.0 billion in aggregate development, regulatory, and commercial milestone payments, plus tiered royalties.
-
Clinical Trial Progress
First patients were dosed in the Phase 1b trial evaluating cemsidomide with elranatamab (March 2026) and the Phase 2 MOMENTUM trial evaluating cemsidomide with dexamethasone (February 2026), indicating advancement in the clinical pipeline.
Analysis · CCCC · Life Sciences
C4 Therapeutics' Q1 2026 report confirms a strong financial position with a cash runway extended through the end of 2028, a critical factor for a clinical-stage biotech. While Q1 revenue decreased, the net loss improved and R&D expenses were reduced. The filing also formalizes the significant new collaboration agreement with Roche, which includes a $20 million upfront payment and potential milestones exceeding $1 billion, providing substantial long-term financial and strategic validation.
At the time of this filing, CCCC was trading at $3.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $309.3M. The 52-week trading range was $1.21 to $3.82. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.